美国ImmunoCellular Therapeutics
IMUC 是一家总部位于洛杉矶的临床阶段公司，致力于开发免疫疗法来治疗脑癌和其它癌症。该公司的先导候选产品 ICT-107 最近进入II期试验，ICT-107 是一种基于树突状细胞的疫苗，该疫苗以多个肿瘤相关抗原为靶向，用于治疗新诊断出的胶质母细胞瘤。

Our mission is to improve cancer treatment and diagnosis through the discovery and development of new immune-based products. Designed to harness both arms of the native immune system, our pipeline includes both active immunotherapies and patented monoclonal antibodies (mABs). Our active immunotherapies target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. Our most advanced clinical programs are in glioblastoma multiforme (GBM), but our technologies have potential applications in many cancers with high unmet medical need, including pancreatic, ovarian, colon, small-cell lung, and multiple myeloma.

Our lead product candidate is ICT-107, a personalized, dendritic cell-based vaccine for the treatment of GBM. We intend to initiate a Phase II study of ICT-107 later this year following the strong results of a Phase I study in which it significantly prolonged survival with minimal side effects. We also intend to file an IND for ICT-121, our peptide-based “off-the-shelf” vaccine for the treatment of GBM.

Our strategy is to become the first company focused primarily on the development of cancer stem cell therapeutics, while working with partners to develop and commercialize our broadly applicable monoclonal antibodies. We have strong intellectual property surrounding our monoclonal antibodies, which were designed with our proprietary discovery technology. We also have an exclusive worldwide licensing agreement with Cedars-Sinai Medical Center for our immunotherapy and cancer stem-cell technologies.